Found 90 clinical trials
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the
- 161 views
- 22 Jan, 2021
- 14 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that
- 45 views
- 24 Jan, 2021
- 3 locations
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib
- 0 views
- 27 Jan, 2021
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)
The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.
- 0 views
- 18 Apr, 2021
- 49 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by
- 4 views
- 28 Jan, 2021
- 63 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with
- 0 views
- 17 Apr, 2021
- 124 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Randomized Open Label Clinical Study of the Targeted Therapy Palbociclib to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine
- 544 views
- 27 Jan, 2021
- 132 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)
This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2
- 0 views
- 24 Jan, 2021
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
. Palbociclib (Ibrance) is the name of the investigational agent, which is assessed together with standard anti-hormone therapy in this study. Palbociclib is used to treat patients with hormone receptor
- 0 views
- 18 Apr, 2021
- 67 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable Hormone Sensitive and HER2-Negative Primary Breast Cancer
The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy
- 43 views
- 16 Apr, 2021
- 27 locations